Physiol. Genomics Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Physiol. Genomics 4: 35-42, 2000;
1094-8341/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WONG, V. Y.
Right arrow Articles by BROOKS, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WONG, V. Y.
Right arrow Articles by BROOKS, D. P.
Received 23 March 2000; accepted in final form 29 August 2000.
Physiological Genomics 4:35-42 (2000)
1094-8341/00 $5.00 © 2000 American Physiological Society

Gene expression in rats with renal disease treated with the angiotensin II receptor antagonist, eprosartan

VICTORIA Y. WONG , NICHOLAS J. LAPING , LISA C. CONTINO , BARBARA A. OLSON , EUGENE GRYGIELKO and DAVID P. BROOKS

Department of Renal Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406

The role of ANG II on renal and cardiac gene expression of matrix proteins was studied in rats with progressive renal disease. Induction of renal failure by five-sixths nephrectomy of Sprague-Dawley rats resulted in hypertension (163 ± 19 vs. control pressures of 108 ± 6 mmHg), proteinuria (83 ± 47 vs. 14 ± 2 mg/day), and increased renal expression of fibronectin, thrombospondin, collagen I and III, transforming growth factor-ß (TGF-ß), and plasminogen activator inhibitor-1 (PAI-1) mRNA. Treatment with the ANG II receptor antagonist, eprosartan (60 mg·kg-1·day-1), lowered blood pressure (95 ± 5 mmHg) and proteinuria (19 ± 8 mg/d) and abrogated the increased TGF-ß, fibronectin, thrombospondin, collagens I and III, and PAI-1 mRNA expression. An increase in left ventricular weight was observed in five-sixths nephrectomized rats (0.13 ± 0.01 vs. 0.08 ± 0.01 g/100 g body wt), a response that was inhibited by eprosartan treatment (0.10 ± 0.01 g/100 g). Left ventricular expression of TGF-ß and fibronectin was also increased in rats with renal disease; however, the small decreases in expression observed in eprosartan-treated rats did not reach statistical significance. These data suggest that eprosartan may be beneficial in progressive renal disease and that the mechanism of action includes inhibition of cytokine production in addition to antihypertensive activity.

transforming growth factor-ß; renal disease; plasminogen activator inhibitor-1




This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. Bertram, N. Blanc-Brunat, J. Sassard, and M. Lo
Differential evolution of blood pressure and renal lesions after RAS blockade in Lyon hypertensive rats
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2002; 283(5): R1041 - R1045.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. T. Abrahamsen, F. C. Barone, W. G. Campbell Jr., A. H. Nelson, L. C. Contino, M. A. Pullen, E. T. Grygielko, R. M. Edwards, N. J. Laping, and D. P. Brooks
The Angiotensin Type 1 Receptor Antagonist, Eprosartan, Attenuates the Progression of Renal Disease in Spontaneously Hypertensive Stroke-Prone Rats with Accelerated Hypertension
J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 21 - 28.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online